Pacira BioSciences reported second-quarter 2026 total revenue of $192.4 million, up 6% from a year earlier, and GAAP net income of $4.7 million, compared with a net loss a year earlier. Non-GAAP net income and adjusted EBITDA both declined year over year, and the company lowered its full-year 2026 total revenue guidance to reflect the completed sale of its iovera business to Zimmer Biomet.
Total revenues were $192.4 million, up from $181.1 million, with EXPAREL net product sales of $147.8 million, up 3%.
GAAP net income was $4.7 million, or $0.12 per share, versus a net loss of $4.8 million, or $0.11 per share, in Q2 2025; non-GAAP net income was $29.5 million, or $0.75 per share basic, down from $36.0 million.
Adjusted EBITDA was $48.7 million, compared with $54.3 million in Q2 2025.
Full-year 2026 total revenue guidance is $735 million to $760 million, down from $745 million to $770 million, reflecting the iovera divestiture that closed July 31, 2026; EXPAREL sales guidance of $600 million to $620 million was reiterate
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Pacira BioSciences, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$726.41M
+3.6%
$0.16
—
1.0%
FY2024
$700.97M
+3.9%
$-2.15
-341.6%
-14.2%
FY2023
$674.98M
+1.2%
$0.89
+161.8%
6.2%
FY2022
$666.82M
+23.1%
$0.34
-63.0%
2.4%
FY2021
$541.53M
+26.0%
$0.92
-72.4%
7.8%
Frequently asked questions
When is Pacira BioSciences's next earnings date?
Pacira BioSciences has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Pacira BioSciences earn last quarter?
For the quarter ended Sep 2026, Pacira BioSciences reported diluted EPS of $0.70 (+483.3% year over year) on revenue of $176.65M (-1.6%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.